Product
Supplier
Encyclopedia
Inquiry
Home > Biochemical Engineering > Polypeptide > Retatrutide for Sale > High purity Retatrutide cas2381089-83-2 with good price
High purity Retatrutide cas2381089-83-2 with good price buy - large image1
High purity Retatrutide cas2381089-83-2 with good price buy - image1
High purity Retatrutide cas2381089-83-2 with good price buy - image2
High purity Retatrutide cas2381089-83-2 with good price buy - image3
High purity Retatrutide cas2381089-83-2 with good price buy - image4
High purity Retatrutide cas2381089-83-2 with good price buy - image5
High purity Retatrutide cas2381089-83-2 with good price buy - image6

High purity Retatrutide cas2381089-83-2 with good price

TDS 7019 Inquiries

Unit Price: Get Latest Price
CAS No.:

2381089-83-2

Grade:

Top Product

Content:

99%

Port:

shanghai

Brand:

COMINGS

Packaging:

1g,50g,100g,1000g

Price valid (until):

2025-05-14

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,100% TT in advance
Average Lead Time:
15 days
Qualification:
Main Products:

semaglutide,tirzepatide,Liraglutide,Retatrutide,5-amino-1MQ,SLU-PP-332

  • Product Description

  • Seller Information

  • Inquiry History

  • Description
    Items Specifications
    CAS:  2381089-83-2
    Name: Retatrutide
    Synonyms Name:

    LY3437943

    Molecular formula: 

    C221H342N46O68

    Molecular Weight:  3751.20000
    Color white


    What is Retatrutide LY3437943?


    •  

      Retatrutide (LY3437943) is a triple insulin-like peptide of the islet gallin-like peptide (GCGR), insulin-glutinin-like peptide-1 receptor (GLP-1R). For human GCGR, GIPR and GLP-1R, the EC50 values ​​are 5.79, 0.0643 and 0.775 nM respectively. Retatrutide may be used in scientific research.

      Retatrutide sequence is a nucleotide composed of four nucleotides (adenine, thymine, guanine and cytosine)

      A linear nucleic acid molecule formed into a specific sequence. It is a segment of a DNA or RNA molecule that has a specific base

      Base pairing mode.



    Application of  Retatrutide


    1.weight loss effect

    Retatrutide treatment at all doses demonstrated clinically meaningful weight loss compared to placebo, with greater weight loss in women

    2.Cardiovascular benefits

    Retatrutide treatment sustained improvements in all lipid levels except HDL (40% reduction in TG; 22% reduction in LDL) and had significant benefits on patients' diastolic and systolic blood pressure.

    3.Security aspect

    Adverse events were reported by 70% of patients in the placebo group; 73% to 94% of patients in the retatrutide group reported adverse events, and the incidence of adverse events was higher in the 8 mg and 12 mg groups. The most common adverse events leading to discontinuation were mild to moderate gastrointestinal reactions, occurring primarily during dose increases


    References:

    1. Alberts B, Johnson ALewis J,et al. Molecular Biology of the

    Cell. 4th edition. New York: Garland Science; 2002.

    2. Lodish H, Berk A, ZipurskySL,et al. Molecular Cell Biology. 4th

    edition. New York: W.H. Freeman; 2000.

    3. Cooper GM, Hausman RE. The Cell: A Molecular Approach. 2nd edition.

    Sunderland (MA):Sinauer Associates; 2000.

    Source: China Medical Tribune Endocrinology Today

    Wuhan Comings Biotechnology Co., Ltd. was established in 2016. Since its establishment, the company has always been committed to making more people healthy, making more people young and happy, and providing customers with high-quality and efficient services.

    The company cooperates with biological experts from many universities, adopts modern gene cloning technology and unique purification technology, and strictly controls all aspects. The adipotide we produce are sold well in Europe, Africa, and America, and many customers have given good reviews.

    And our company has storage bases in Shenzhen, Shanghai, Qingdao ports to ensure that all goods can arrive safely, on time and quickly.

    Wuhan Comings Biotechnology Co., Ltd. is looking forward to cooperating with you with professional knowledge, high-quality service and competitive price!

    Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 1

    Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 2Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 3Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 4Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 5

    Shop Weight Loss GLP-1 Injection Peptide 99% Purity Tirzepatide(LY3298176) Semaglutide/COMINGS-Detailed Image 6

    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Certificates
    • High purity Retatrutide cas2381089-83-2 with good price Certificates 1 TDS

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Categories:

    Polypeptide

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    semaglutide,tirzepatide,Liraglutide,Retatrutide,5-amino-1MQ,SLU-PP-332

    Location:

    No. 1, 19th Floor, Unit 2, Building 5, Southeast Residential Building (Hankou Yujiang Lanting), at the intersection of Hanshi Highway and Fufa South Road, Wuhu Street, Huangpi District, Wuhan City, Hu

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Average lead Time:

    15 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2023

    We prospectively allocates international cutting-edge production and testing equipment and environmental protection facilities. The 5 production lines can achieve an annual output of 1000Kg. We to be the best chemical manufacture in China,and will become a trustworthy supplier of chemicals for global customers.
    Our main products include peptides, cognitive enhancers, pharmaceutical intermediates, and botanical extracts.
    And our main clients cover: pharmaceutical companies, hospitals, laboratories in higher education institutions, and cosmetic companies.
    Since its establishment, our company's products have been exported to regions including Europe, the Americas, the Middle East and so on. Our commitment to high product quality and excellent after-sales service has provided customers with a positive experience.
    Wuhan Comings Biotechnology Co., Ltd. is looking forward to cooperating with you with professional knowledge, high-quality service and competitive price!
  • Inquiry History
    7019 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Retatrutide 2381089-83-2

    3 MT Mar 28, 2026
    United Kingdom

    Retatrutide - 2381089-83-2

    1 G Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 10mg vial

    20 MT Mar 7, 2026
    United States

    Factory Retatrutide API 99% Purity CAS 2381089-83-2

    5 KG Nov 10, 2025
    United Kingdom

    Peptide powder Retatrutide 99% pure for Body building cas 2381089-83-2 Weight Loss Peptide with COA

    1 MT Mar 22, 2026
    United States

    2381089-83-2

    100 MT Dec 9, 2023
    United States

    2381089-83-2

    100 G Jul 14, 2026
    United States

    2381089-83-2

    100 G Feb 24, 2026
    United States

    Retatrutide 2381089-83-2

    200 MG May 16, 2026
    United Kingdom

    2381089-83-2 retatrutide

    300 MG Feb 13, 2026
    United States

    Retatrutide 2381089-83-2 wholesale

    500 MT Nov 3, 2023
    Poland

    CAS 2381089-83-2 (Custom Peptide)

    40 MT Apr 10, 2026
    Austria

    Peptide Retatruide CAS 2381089-83-2

    100 MT Apr 4, 2026
    Austria

    Retatrutide CAS 2381089-83-2 10mg vial

    20 PCS Feb 10, 2026
    United States

    Retatrutide CAS 2381089-83-2 99%

    10 PCS Feb 21, 2026
    United States

    GLP-1 / GIP Retatrutide cas 2381089-83-2

    1 MT Oct 16, 2024
    Australia

    GMP Grade 99% Retatrutide Lyophilized Powder CAS 2381089-83-2

    10 G Jun 12, 2026
    United States

    Retatrutide 99% High Quality CAS 2381089-83-2

    1 G Jan 23, 2026
    Poland

    Factory 99% Purity Retatrutide Peptide CAS 2381089-83-2 Door-To-Door Service

    5 G Feb 22, 2026
    United States

    Injection Peptide Tirzepatide/Retatrutide/ Semaglutide Peptides CAS 2381089-83-2

    10  Oct 21, 2023
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.